Retrospective Chart Review of Subcutaneous IgG Use in Infants

Completed

Conditions studied: Primary Immune Deficiency

In brief

This study is a retrospective chart review of the use of subcutaneous IgG (SCIG) in infants less than two years old.

Key facts

Study ID

NCT01166074

Run by

CSL Behring

People needed

27

Starts

2010-05-01

Expected to finish

2010-12-01

Last updated by the study team

2011-02-11

Who can join

Age: any, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants who received more than one dose of IgG by the subcutaneous route before the age of two years.
• Consent of parent/guardian if required by institution/IRB.

You may not qualify if…

• Infants with protein losing conditions such as lymphangiectasis, nephrosis, S/P cardio-thoracic surgery requiring drainage tubes for more than 48 hrs, protein losing enteropathy.
• Concomitant treatment with plasma, other blood products or IGIV while on SCIG.
• Lack of consent by parent/guardian (if required by Institution/IRB).
• Any other condition or treatment which, in the opinion of the local investigator, would interfere with obtaining valid results for that subject.

Where it is running

• Children's Hospital of Los Angeles — Los Angeles, California, United States
• University of South Florida — Tampa, Florida, United States
• Midwest Immunology Clinic — Plymouth, Minnesota, United States
• University Hospitals Case Medical Center — Cleveland, Ohio, United States
• St. Judes Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.